Phase 1 IDH1 Mutation Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1Phase 2

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

TreatmentAMLIDH1 Mutation

Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06611839

Recruiting

Phase 1Phase 2

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Institut de Recherches Internationales Servier52 enrolled37 locationsNCT06501625